Evidence map›Paper›PMID 36874152›Full record

ArticleFrontiers in immunology2022

The epidemic of the multiresistant dermatophyte

Songgan Jia, Xuemei Long, Wei Hu, Jiali Zhu, Yinhui Jiang, Sarah Ahmed, G Sybren de Hoog, Weida Liu, Yanping Jiang

Abstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Dermatophytosis: An Update on Global Epidemiology.Journal of fungi (Basel, Switzerland) · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. A Chinese warning: Terbinafine-resistant Trichophyton indotineae, a global dermatological challenge.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Article
  13. Review
  14. Article
  15. Review
  16. Emerging antifungal resistance inEmerging microbes & infections · 2025
    Article
  17. Article
  18. Review
  19. Article
  20. National Belgian Study on Terbinafine Resistance inJournal of fungi (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Songgan JiaDepartment of Dermatology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Xuemei LongDepartment of Dermatology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Wei HuDepartment of Dermatology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Jiali ZhuDepartment of Dermatology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Yinhui JiangLaboratory of Medical Molecular Biology, Guizhou Medical University, Guiyang, China.
Sarah AhmedCentre of Expertise in Mycology, Radboud University Medical Center/Canisius Wilhelmina Hospital, Nijmegen, Netherlands.
G Sybren de HoogCentre of Expertise in Mycology, Radboud University Medical Center/Canisius Wilhelmina Hospital, Nijmegen, Netherlands.
Weida LiuDepartment of Medical Mycology, Institute of Dermatology, Chinese Academy of Medical Science & Peking Union Medical College, Nanjing, China.
Yanping JiangDepartment of Dermatology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to its high degree of natural resistance to terbinafine

Indexed as

ArthrodermataceaeEpidemicsAsian PeopleChinaHumansTrichophytonarthrodermataceaeChinagenotypenatural resistancerecombination

Identifiers

PMID36874152
PMCPMC9978415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.